← PCSK9 inhibitors × cardiovascular events

TrialCirculation2018

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.

Aruna D Pradhan et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 9,738 people · 2018

Not counted

Reduced cardiovascular events

−60.5percentage points−61.2 to −59.8

As reported

difference −60.5 %, 95% CI −61.2 to −59.8

One number in the abstract

the abstract, start to end

… additionally received bococizumab was -60.5% (95% confidence interval [CI], …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
−60.5−61.2 to −59.8
StatinsPCSK9 inhibitorsCardiovascular events
1 / 3

129 papers cite itlatest 60 shown

2018
…
2019
2020
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 29716940